Twist Bioscience (NASDAQ:TWST) Shares Up 6%

Twist Bioscience Corp (NASDAQ:TWST)’s stock price shot up 6% during mid-day trading on Friday . The company traded as high as $24.87 and last traded at $24.74, 190,779 shares were traded during mid-day trading. A decline of 12% from the average session volume of 217,433 shares. The stock had previously closed at $23.34.

Several brokerages have issued reports on TWST. ValuEngine upgraded Twist Bioscience from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Zacks Investment Research downgraded Twist Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, October 5th.

The company has a current ratio of 7.18, a quick ratio of 6.96 and a debt-to-equity ratio of 0.03. The company’s fifty day simple moving average is $23.27 and its 200 day simple moving average is $26.53.

In other Twist Bioscience news, CTO Bill Peck sold 19,553 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $30.06, for a total transaction of $587,763.18. Also, SVP Mark Daniels sold 1,500 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $29.90, for a total value of $44,850.00. Insiders sold 258,170 shares of company stock valued at $6,556,041 in the last quarter. Corporate insiders own 29.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Elkfork Partners LLC grew its position in Twist Bioscience by 100.0% during the second quarter. Elkfork Partners LLC now owns 924 shares of the company’s stock worth $27,000 after buying an additional 462 shares in the last quarter. Meadow Creek Investment Management LLC boosted its position in shares of Twist Bioscience by 100.0% during the 2nd quarter. Meadow Creek Investment Management LLC now owns 1,176 shares of the company’s stock valued at $34,000 after acquiring an additional 588 shares during the last quarter. Glen Harbor Capital Management LLC grew its holdings in shares of Twist Bioscience by 100.0% during the second quarter. Glen Harbor Capital Management LLC now owns 1,428 shares of the company’s stock worth $41,000 after purchasing an additional 714 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Twist Bioscience by 536.9% during the second quarter. Tower Research Capital LLC TRC now owns 1,484 shares of the company’s stock worth $43,000 after purchasing an additional 1,251 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Twist Bioscience by 87,550.0% in the second quarter. Bank of Montreal Can now owns 1,753 shares of the company’s stock worth $51,000 after purchasing an additional 1,751 shares during the last quarter. Institutional investors own 47.74% of the company’s stock.

About Twist Bioscience (NASDAQ:TWST)

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Recommended Story: How Investors Use a Balance Sheet

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.